Redefining mental health to enable people to thrive
At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.
Search
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
An Employee’s Commitment to Ensuring Access to Medicines
An Employee’s Commitment to Ensuring Access to Medicines
Country Management Committee: A Message | Boehringer Ingelheim US
Click here to read a statement from Boehringer Ingelheim on the tragic events in Uvalde, TX and how BI Cares is supporting victims and families.
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
How Simulation is Changing the Game in Biotherapeutic Drug Development
How Simulation is Changing the Game in Biotherapeutic Drug Development
Clinical Development and Operations
Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
Making Toys for Shelter Animals | Boehringer Ingelheim US
Find out how nearly 400 Boehringer Ingelheim employees came together to make toys out of donated t-shirts for animals living in shelters across the USA.
Interdisciplinary approach to CKM care
Explore the global impact of Cardiovascular- Kidney- Metabolic (CKM) syndrome, and the need for an integrated approach to manage these interconnected conditions. Insights from experts at Boehringer Ingelheim and George Washington University.
Biopharma Contract Manufacturing
Biopharma Contract Manufacturing
Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic
Pet shelters impacted by the COVID-19 pandemic have benefitted from the Stay Home and Foster program, which connects shelter pets with foster homes.
Jardiance® (empagliflozin) Shows Reduction in CV Risk & Death | Boehringer Ingelheim US
BI & Eli Lilly & Co.’s JARDIANCE reduced risk of CV death, non-fatal heart attack or non-fatal stroke by 14%. View ISI, PI and Med Guide.
US Privacy Statement
US Privacy Statement
New GPP Consensus Statement Released
National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)
Prescription Digital Therapeutics a New Frontier in Mental Health Care
Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.
Vetmedica, Inc. Opens New R&D Facility | Boehringer Ingelheim US
Find out more on the opening of Boehringer Ingelheim Vetmedica Inc's new research and development facility in Ames, Iowa.
BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US
BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.
Interview with Michael Schmelmer
"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Sustainable Development - Our Commitment
Our Commitment
Poultry vaccine site in Georgia continues to reduce carbon emissions
Going carbon neutral has resulted in measurable, positive impacts. From 2021 to 2022, the Gainesville site reduced its CO2 emissions by 23 percent – nearly 700 fewer tons of CO2 emissions are released into the atmosphere
FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US
FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.
FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US
Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.
Scam alert
Scam alert
Meet the Animal Health Partnering Team
Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.